Chymase Inhibitors

Title:Chymase Inhibitors

Volume: 19 Issue: 17

Author(s): Eiji Yahiro, Shin-ichiro Miura, Satoshi Imaizumi, Yoshinari Uehara and Keijiro Saku

Affiliation:

Keywords: Local renin-angiotensin system, angiotensin II-forming pathways, angiotensin converting enzyme inhibitor, angiotensin II type 1 receptor blockers.

Abstract: Chymase, a chymotrypsin-like serine protease that is abundant in secretory granules from mast cells, has been identified to be a key enzyme in the local renin-angiotensin system (RAS) that generates angiotensin II (Ang II) independent of angiotensin converting enzyme (ACE). The pathophysiological significance of alternative Ang II-forming pathways in human cardiovascular disease remains controversial. Although chymase inhibitors, unlike ACE inhibitors and Ang II type 1 receptor blockers (ARBs), may only play a small role in the regulation of the systemic RAS, the possible applications of chymase inhibitors as new drugs that inhibit the local RAS to prevent cardiovascular diseases are described in animal models. In this review, we discuss the possible application of chymase inhibitors as new drugs to inhibit the RAS in mainly cardiovascular diseases.

Cite this article as:

Yahiro Eiji, Miura Shin-ichiro, Imaizumi Satoshi, Uehara Yoshinari and Saku Keijiro, Chymase Inhibitors, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170014